We've changed our Twitter account. Please follow us now at @ionispharma. Our new ticker symbol has also changed to $IONS.

Isis Pharmaceuticals Changes Name to Ionis Pharmaceuticals: Company's Shares Will Trade Under New Ticker Symbo... bit.ly/1RWGSP3

Isis Pharmaceuticals Announces Initiation of an Investigator-Sponsored Phase 2 Study of ISIS-TTR Rx in Patient... bit.ly/1UDRHF2

Isis Pharmaceuticals Announces Initiation of Phase 1/2 Clinical Study of ISIS-SOD1 Rx in Patients With ALS: CA... bit.ly/1Q6N9YY

Isis Pharmaceuticals Earns $2.8M for Advancing ISIS-DMPK-2.5 Rx in Patients with Myotonic Dystrophy Type I: CA... bit.ly/1QrrcSY

Isis Reports Financial Results and Highlights for Third Quarter 2015: - 2015 Pro Forma Net Income of $25 Milli... bit.ly/1NEoMjo

Isis Pharmaceuticals Reports Positive Clinical Data From Lp(a) Lowering Drugs: Webcast to review data schedule... bit.ly/1HnowUB

Isis Pharmaceuticals to Present at Upcoming Investor Conferences: CARLSBAD, Calif., Nov. 6, 2015 /PRNewswire/ ... bit.ly/1HwsAwB

Isis Pharmaceuticals and Akcea Therapeutics Announce Start of Phase 3 Study of Volanesorsen in Patients with F... bit.ly/1WCcYhZ

Isis Pharmaceuticals to Host Webcast to Review ISIS-APO(a) Rx and ISIS-APO(a)-L Rx Data Presented at American ... bit.ly/1QbRYPi

Isis Pharmaceuticals Reports an Update on ISIS-TTR Rx, Including Positive Data from Multiple Clinical Studies,... bit.ly/1H2Sj4I

Isis Pharmaceuticals Initiates Phase 2 Study of ISIS-FXI Rx in Patients with End-Stage Renal Disease on Hemodi... bit.ly/1GOOUq9

Isis Pharmaceuticals to Host Webcast to Review ISIS-TTR Rx Data Presented at 1st European Congress of Heredita... bit.ly/1MoUmm9

ISIS Pharmaceuticals Earns $5 Million from GSK for Initiation of Phase 1 Study of ISIS-GSK4-L Rx: CARLSBAD, Ca... bit.ly/1MlWcny

Webcast Alert: Isis Pharmaceuticals' Third Quarter 2015 Financial Results Conference Call: - Webcast scheduled... bit.ly/1Me74nB

Isis Pharmaceuticals Initiates SHINE Study to Provide ISIS-SMN Rx for Patients With SMA Who Have Completed the... bit.ly/1LQpy7a

ISIS-DMPK-2.5Rx for DM1 ongoing phase I/II trial update at 2015 MDF conference. bit.ly/1NPkPHx @CareAndACureMDF @DM1research

Surfing Dog Helps Kids with SMA Ride The Waves! #SMAshSMA thedodo.com/surfing-dog-give…

Isis Pharmaceuticals' Collaboration to Discover and Develop Antisense Drugs for Cardiovascular, Metabolic and ... bit.ly/1K08POM

Isis Pharmaceuticals to Present at Upcoming Investor Conferences: CARLSBAD, Calif., Sept. 3, 2015 /PRNewswire/... bit.ly/1LNiVFo